MedKoo Cat#: 562891 | Name: Cinanserin HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cinanserin HCl is an inhibitor of CRP-XL- and collagen-induced Ca2+ release and aggregation. It also acts as an inhibitor of GPVI-mediated cell activation.

Chemical Structure

Cinanserin HCl
Cinanserin HCl
CAS#54-84-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 562891

Name: Cinanserin HCl

CAS#: 54-84-2 (HCl)

Chemical Formula: C20H25ClN2OS

Exact Mass: 376.1376

Molecular Weight: 376.94

Elemental Analysis: C, 63.73; H, 6.69; Cl, 9.40; N, 7.43; O, 4.24; S, 8.51

Price and Availability

Size Price Availability Quantity
10mg USD 450.00 2 Weeks
50mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Cinanserin HCl; Cinanserin Hydrochloride; SQ-10643; SQ 10643; SQ10643; NSC-125717; NSC 125717; NSC125717;
IUPAC/Chemical Name
(E)-N-[2-[3-(Dimethylamino)propylsulfanyl]phenyl]-3-phenylprop-2-enamide hydrochloride
InChi Key
LXGJPDKYMJJWRB-IERUDJENSA-N
InChi Code
InChI=1S/C20H24N2OS.ClH/c1-22(2)15-8-16-24-19-12-7-6-11-18(19)21-20(23)14-13-17-9-4-3-5-10-17;/h3-7,9-14H,8,15-16H2,1-2H3,(H,21,23);1H/b14-13+;
SMILES Code
O=C(NC1=CC=CC=C1SCCCN(C)C)/C=C/C2=CC=CC=C2.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 376.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chiow KH, Phoon MC, Putti T, Tan BK, Chow VT. Evaluation of antiviral activities of Houttuynia cordata Thunb. extract, quercetin, quercetrin and cinanserin on murine coronavirus and dengue virus infection. Asian Pac J Trop Med. 2016 Jan;9(1):1-7. doi: 10.1016/j.apjtm.2015.12.002. Epub 2015 Dec 19. PMID: 26851778; PMCID: PMC7104935. 2: Hernekamp JF, Hu S, Schmidt K, Walther A, Kneser U, Kremer T. Cinanserin reduces plasma extravasation after burn plasma transfer in rats. Burns. 2013 Sep;39(6):1226-33. doi: 10.1016/j.burns.2013.01.005. Epub 2013 Mar 21. PMID: 23523219. 3: Millonig RC, Amrein BJ, Kirschbaum J, Hess SM. Immunosuppressive and antiinflammatory activities of cinanserin and its analogs. J Med Chem. 1974 Jul;17(7):772-5. doi: 10.1021/jm00253a031. PMID: 4836414. 4: Mosaffa S, Ahmadi H, Khakpai F, Ebrahimi-Ghiri M, Zarrindast MR. Synergistic antidepressant- and anxiolytic-like effects of harmaline along with cinanserin in acute restraint stress-treated mice. Psychopharmacology (Berl). 2021 Jan;238(1):259-269. doi: 10.1007/s00213-020-05679-6. Epub 2020 Nov 14. PMID: 33190164; PMCID: PMC7666640. 5: Chen L, Gui C, Luo X, Yang Q, Günther S, Scandella E, Drosten C, Bai D, He X, Ludewig B, Chen J, Luo H, Yang Y, Yang Y, Zou J, Thiel V, Chen K, Shen J, Shen X, Jiang H. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol. 2005 Jun;79(11):7095-103. doi: 10.1128/JVI.79.11.7095-7103.2005. PMID: 15890949; PMCID: PMC1112131. 6: Babington RG, Wedeking PW. The influence of cinanserin and selected pharmacologic agents on experimental allergic encephalomyelitis (EAE). J Pharmacol Exp Ther. 1971 May;177(2):454-60. PMID: 4254977. 7: Winter JC. Comparison of chlordiazepoxide, methysergide, and cinanserin as modifiers of punished behavior and as antagonists of N,N-dimethyltryptamine. Arch Int Pharmacodyn Ther. 1972 May;197(1):147-59. PMID: 5064096. 8: Yang Q, Chen L, He X, Gao Z, Shen X, Bai D. Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors. Chem Pharm Bull (Tokyo). 2008 Oct;56(10):1400-5. doi: 10.1248/cpb.56.1400. PMID: 18827378. 9: Itil TM, Polvan N, Holden JM. Clinical and electroencephalographic effects of cinanserin in schizophrenic and manic patients. Dis Nerv Syst. 1971 Mar;32(3):193-200. PMID: 4929084. 10: Metcalfe HL, Turner P. Pharmacological studies of cinanserin in human isolated smooth muscle. Br J Pharmacol. 1969 Oct;37(2):519P-521P. PMID: 5348442; PMCID: PMC1703698. 11: Holden JM, Keskiner A, Gannon P. A clinical trial of an antiserotonin compound, cinanserin, in chronic schizophrenia. J Clin Pharmacol New Drugs. 1971 May-Jun;11(3):220-6. PMID: 4946100. 12: Ambinder EP, Schwartz GH, Rubin AL, Stenzel KH. Prolongation of survival of skin homografts in mice with cinanserin alone and in combination with azathioprine. Transplantation. 1969 Feb;7(2):147-9. doi: 10.1097/00007890-196902000-00008. PMID: 4884917. 13: Gallant DM, Bishop MP. Cinanserin (SQ. 10,643): a preliminary evaluation in chronic schizophrenic patients. Curr Ther Res Clin Exp. 1968 Sep;10(9):461-3. PMID: 4971651. 14: Rosen AJ, Cohen ME. The effects of cinanserin, a potent serotonin antagonist, on the acquisition of a running response in the rat. Neuropharmacology. 1973 Jun;12(6):501-8. doi: 10.1016/0028-3908(73)90001-4. PMID: 4725521. 15: Mele PC, Caplan MA. Effects of cinanserin and p-chlorophenylalanine and their interaction with d-amphetamine on DRL performance in rats. Pharmacol Biochem Behav. 1980 Jun;12(6):883-91. doi: 10.1016/0091-3057(80)90449-9. PMID: 6447298. 16: Pontiki E, Peperidou A, Fotopoulos I, Hadjipavlou-Litina D. Cinnamate Hybrids: A Unique Family of Compounds with Multiple Biological Activities. Curr Pharm Biotechnol. 2018;19(13):1019-1048. doi: 10.2174/1389201019666181112102702. PMID: 30417783. 17: Geller I, Hartmann RJ, Messiha FS. Effect of cinanserin, a serotonin antagonist on ethanol preference in the rat. Proc West Pharmacol Soc. 1975;18:141-5. PMID: 1178659. 18: Winter JC. Morphine and ethanol as discriminative stimuli: absence of antagonism by p-chlorophenylalanine methyl ester, cinanserin, or BC-105. Psychopharmacology (Berl). 1977 Jul 18;53(2):159-63. doi: 10.1007/BF00426486. PMID: 142996. 19: Malick JB, Doren E, Barnett A. Quipazine-induced head-twitch in mice. Pharmacol Biochem Behav. 1977 Mar;6(3):325-9. doi: 10.1016/0091-3057(77)90032-6. PMID: 140381. 20: Barasi S, Roberts MH. Proceedings: The effects of cinanserin and phentolamine applied by microiontophoresis in the spinal cord. Br J Pharmacol. 1975 Jun;54(2):237P. PMID: 1148525; PMCID: PMC1666654.